3.93  -0.12 (-2.96%)		07-26 16:00
Open: 4.02 High: 4.06 Volume: 47,699		Pre. Close: 4.05 Low: 3.9101 Market Cap: 119(M)

Short term
Mid term
Targets	6-month :	5.22	1-year :	6.09
Resists	First :	4.46	Second :	5.22
Pivot price	3.97
Supports	First :	3.52	Second :	2.94
MAs	MA(5) :	4.03	MA(20) :	3.73
	MA(100) :	3.96	MA(250) :	3.66
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	69	D(3) :	70.8
RSI	RSI(14): 57.4
52-week	High :	7.22	Low :	2.41

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RLMD ] has closed above bottom band by 45.4%. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.07 - 4.09	4.09 - 4.12
Low:	3.85 - 3.87	3.87 - 3.9
Close:	3.88 - 3.93	3.93 - 3.97

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Thu, 25 Jul 2024
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - PR Newswire

Thu, 11 Jul 2024
Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership - Yahoo Finance

Thu, 11 Jul 2024
Institutional investors are Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) biggest bettors and were rewarded after last week's US$38m market cap gain - Simply Wall St

Tue, 09 Jul 2024
Relmada Therapeutics (NASDAQ:RLMD) Shares Up 5.6% - MarketBeat

Mon, 10 Jun 2024
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - BioSpace

Wed, 08 May 2024
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	30 (M)
Shares Float	28 (M)
Held by Insiders	8 (%)
Held by Institutions	49.2 (%)
Shares Short	1,010 (K)
Shares Short P.Month	1,540 (K)

EPS	-3.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.39
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-56 %
Return on Equity (ttm)	-95.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-48 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-1.26
PEG Ratio	0
Price to Book value	1.64
Price to Sales	0
Price to Cash Flow	-2.47

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.